^(89)SrCl_2联合唑来膦酸治疗前列腺癌骨转移的临床疗效与安全性观察

Clinical efficacy and safety of ^(89)SrCl_2 combined with zoledronic acid in the treatment of bone metastasis of patients with prostate cancer

目的:观察氯化锶(89Sr Cl2)联合唑来膦酸治疗前列腺癌骨转移的临床效果与安全性。方法:选择183例前列腺癌骨转移伴骨痛病例,随机分为89Sr Cl2联合唑来膦酸组(A组,68例)、89Sr Cl2联合锝-99-亚甲基二膦酸盐(99Tc-MDP)组(B组,64例)及99Tc-MDP组(C组,51例),观察各组缓解骨痛、骨转移、生活质量改善和不良反应情况。结果:治疗后A组骨痛缓解有效率(88.23%)高于B组(75.00%,P=0.049)和C组(68.63%,P=0.008);A组骨转移减少率为48.53%,高于C组(29.41%,P=0.035);A组生活质量改善率为61.76%,高于C组(41.18%,P=0.004);B组和C组的骨痛缓解有效率、骨转移减少率、生活质量比较,差异均无统计学意义;3组不良反应比较,差异无统计学意义。结论:89Sr Cl2联合唑来膦酸治疗前列腺癌骨转移在骨痛缓解、骨转移减少及生活质量改善等方面均优于89Sr Cl2,较89Sr Cl2联合99Tc-MDP治疗方式简捷,安全性良好,值得临床推广。

Objective：To observe the clinical efficacy and safety of 89 SrCl2 combined with zoledronic in treatment of prostate cancer with bone metastasis. Methods： One hundred and eighty-three cases of prostate cancer with bone metastasis were randomly divided into 3 groups：89SrCl2 combined with zoledronic acid group （group A ,68 cases）, 89SrCl2 combined with99Tc-MDP group （group B,64 cases） and 89SrCl2 alone group （group C,51 cases）. The oc- currence of bone pain,bone metastasis, quality of life improvement and adverse reactions of the 3 groups were ob- served. Results：After treatment, the remission rate of bone pain in group A （88.23%） was higher than that in group B （75.00% ,P =0.049） and group C （68.63% ,P = 0.008）. The reduction rate of bone metastasis in group A was 48.53% ,significantly higher than that in group C （29.41%, P =0.035） ;the quality of life improved rate in group A was 61.76% ,significantly higher than that in group C （41.18%, P = 0. 004） ;there were no statistically significantdifferences for the remission rate of bone pain, rate of decrease of bone metastasis, and quality of life improvement between the group B and group C and there was no significant difference in the adverse reactions in the 3 groups. Conclusion：89srCl2 combined with zoledronic acid therapy can relieve bone pain and bone metastasis, and improve quality of life without additional adverse reactions ,and it＇s worth clinical promotion.